Zydus Lifesciences Ltd.

Cadila Healthcare has received a letter from US Food and Drug Administration (USFDA), conveying that the facilities at Moraiya are acceptable. The USFDA had earlier issued a warning letter to the company but with this it is been resolved.

Cadila Healthcare focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

The company has posted a rise of 55.30% in its net profit at Rs 139.40 crore for the quarter ended March 31, 2012 as compared to Rs 89.76 crore for the same quarter in the previous year. Total income has increased by 13.95% at Rs 795.86 crore for quarter under review as compared Rs 698.41 crore for the quarter ended March 31, 2011.